<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166365">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737398</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 420915-CS2</org_study_id>
    <nct_id>NCT01737398</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ISIS-TTRRx in Familial Amyloid Polyneuropathy</brief_title>
  <official_title>A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Isis Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Ministry of Health</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ISIS TTR Rx given for 65
      weeks in patients with Familial Amyloid Polyneuropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial Amyloid Polyneuropathy (FAP) is a rare, hereditary disease caused by mutations in
      the transthyretin (TTR) protein.  TTR is made by the liver and secreted into the blood.  TTR
      mutations cause it to misfold and deposit in multiple organs causing FAP.

      ISIS TTR Rx is an antisense drug that decreases the amount of mutant and normal TTR made by
      the liver.  It is predicted that decreasing the amount of TTR protein will result in a
      decrease in the formation of TTR deposits, and thus slow or stop disease progression.

      The purpose of this study is to determine if ISIS TTR Rx can slow or stop the nerve damage
      caused by TTR deposits.  This study will enroll late Stage 1 and early Stage 2 FAP patients.
       Patients will receive either ISIS TTR Rx or placebo for 65 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of ISIS TTR Rx as measured by change from baseline in the modified Neuropathy Impairment Score +7</measure>
    <time_frame>65 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of ISIS TTR Rx as measured by change from baseline in the Norfolk Quality of Life Diabetic Neuropathy questionnaire</measure>
    <time_frame>65 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ISIS TTR Rx based on the change from baseline in the following measures:</measure>
    <time_frame>65 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified Body Mass Index and Body Mass Index
Individual components of the mNIS+7
NIS+7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect of ISIS TTR Rx based on the change from baseline in transthyretin and retinol binding protein 4</measure>
    <time_frame>65 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Familial Amyloid Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>ISIS TTR Rx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS TTR Rx</intervention_name>
    <description>300 mg ISIS TTR Rx administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.</description>
    <arm_group_label>ISIS TTR Rx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 1 and Stage 2 FAP patients with the following:

               1. NIS score &gt;15 and &lt;85

               2. Ability to walk unaided or with the use of no more than one stick/cane

               3. Documented transthyretin variant by genotyping

               4. Documented amyloid deposit by biopsy

          -  Females of child-bearing potential must use appropriate contraception and must be
             non-pregnant and non-lactating. Males engaged in relations of child-bearing potential
             must use appropriate contraception

        Exclusion Criteria:

          -  Low Retinol level at screen

          -  Karnofsky performance status ≤50

          -  Poor Renal function

          -  Known type 1 or type 2 diabetes mellitus

          -  Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease)

          -  If previously treated with Vyndaqel®, must have discontinued treatment for 2 weeks
             prior to Study Day 1. If previously treated with Diflunisal, must have discontinued
             treatment for 3 days prior to Study Day 1

          -  Previous treatment with any oligonucleotide or siRNA within 12 months of screening

          -  Prior liver transplant or anticipated liver transplant within 1 yr of screening

          -  New York Heart Association (NYHA) functional classification of ≥3

          -  Acute Coronary Syndrome or major surgery within 3 months of screening

          -  Known Primary or Leptomeningeal Amyloidosis

          -  Anticipated survival less than 2 years

          -  Have any other conditions in the opinion of the investigator which could interfere
             with the patient participating in or completing the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isis Pharmaceuticals</last_name>
    <phone>800-679-4747</phone>
    <email>patients@isisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Martin</last_name>
      <phone>714-456-7760</phone>
      <email>vero@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Annabel Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merrill Benson, MD</last_name>
      <phone>317-278-3426</phone>
      <email>mdbenson@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Merrill Benson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Burks</last_name>
      <phone>410-502-6006</phone>
      <email>kburks1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Polydefkis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine - Amyloid Treatment &amp; Research Program</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Pappin</last_name>
      <phone>617-638-4494</phone>
      <email>Samantha.Pappin@bmc.org</email>
    </contact>
    <investigator>
      <last_name>John Berk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morie Gertz, MD</last_name>
      <phone>507-284-2511</phone>
      <email>Gertz.morie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Morie Gertz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - The Neurological Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Brannagan</last_name>
      <phone>212-305-0405</phone>
      <email>tb2325@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Brannagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghimja Berhanu</last_name>
      <phone>212-241-1617</phone>
      <email>ghimja.berhanu@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Gorevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor - Department of Neurology</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Plante</last_name>
      <phone>+33 6 62 32 83 91</phone>
      <email>vplante@free.fr</email>
    </contact>
    <investigator>
      <last_name>Violaine Plante-Bordeneuve, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bicetre Aphp French Referral Center for FAP/Cornamyl Network</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof David Adams</last_name>
      <phone>+33 1 45 21 27 11</phone>
      <email>david.adams@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>David Adams, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKM; Universitätsklinikum Münster, Klinik für Transplantationsmedizin</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hartmut Schmidt, Prof.</last_name>
      <phone>+49 251 83 57935</phone>
      <email>hepar@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Hartmut Schmidt, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giampaolo Merlini, Prof.</last_name>
      <phone>+39(0)382-502994</phone>
      <email>gmerlini@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Giampaolo Merlini, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHLN - Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dra. Conceicao</last_name>
      <phone>+351 217 930 629</phone>
      <email>imsconceicao@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Isabel Conceicao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHP-HGSA, Unidade Clinica de Paramiloidose</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dra. Teresa Coelho</last_name>
      <phone>+351 226 068 114</phone>
      <email>tcoelho@netcabo.pt</email>
    </contact>
    <investigator>
      <last_name>Teresa Coelho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London - National Amyloidosis Centre</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thirusha Lane</last_name>
      <phone>020 7433 2759</phone>
      <email>t.lane@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Carol Whelan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FAP</keyword>
  <keyword>Familial Amyloid Polyneuropathy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
